Excerpts
Two former Merck scientists, who filed a whistleblower lawsuit accusing the drug maker of falsifying data about its mumps vaccine, say the company is refusing to answer a key question about effectiveness of the product, according to court documents.
The lawsuit has gained attention because it comes at a time of ongoing controversy over vaccine safety, in general, and resistance by some parents to having their children vaccinated. The issue was highlighted again last year after a measles outbreak at Disneyland in California, where 147 people were infected, prompting push back against religious exemptions for vaccination.
The mumps vaccine is a sizeable product for Merck, which reported that sales reached $721 million last year, when including both the MMR II vaccine – which is mumps, measles and rubella – and the ProQuad vaccine, a combination product that is also used to thwart chickenpox, according to a filing with the U.S. Securities and Exchange Commission (see page 49).
The original article here:
http://blogs.wsj.com/pharmalot/2015/06/08/merck-is-accused-of-stonewalling-over-effectiveness-of-mumps-vaccine/
Two former Merck scientists, who filed a whistleblower lawsuit accusing the drug maker of falsifying data about its mumps vaccine, say the company is refusing to answer a key question about effectiveness of the product, according to court documents.
The lawsuit has gained attention because it comes at a time of ongoing controversy over vaccine safety, in general, and resistance by some parents to having their children vaccinated. The issue was highlighted again last year after a measles outbreak at Disneyland in California, where 147 people were infected, prompting push back against religious exemptions for vaccination.
The mumps vaccine is a sizeable product for Merck, which reported that sales reached $721 million last year, when including both the MMR II vaccine – which is mumps, measles and rubella – and the ProQuad vaccine, a combination product that is also used to thwart chickenpox, according to a filing with the U.S. Securities and Exchange Commission (see page 49).
The original article here:
http://blogs.wsj.com/pharmalot/2015/06/08/merck-is-accused-of-stonewalling-over-effectiveness-of-mumps-vaccine/